We use cookies to ensure that we give you the best experience on our website Learn more

Jun 27, 2018

MASCC/ISOO Annual Meeting on Supportive Care in Cancer

11 / COMPLEMENTARY THERAPIES FOR THE PREVENTION AND MANAGEMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY

Kalisch;

A.;

Rostock;

M.;

Stapf;

A.;

Steinmann;

D.;

Horneber;

M.A.

complementary therapies

chemotherapy-induced peripheral neuropathy

taxanes

platinum agents

cipn

Abstract

Abstract

thumbnail

Keywords

complementary therapies

chemotherapy-induced peripheral neuropathy

taxanes

platinum agents

cipn

Abstract

Introduction Chemotherapy induced peripheral neuropathy (CIPN), is a severe problem in oncology leading to dose reduction, treatment delay or discontinuation. Complementary therapies (CT) are supportive measures used as adjuncts to mainstream cancer care to control symptoms and enhance well-being. Objectives To update the available evidence about the efficacy and safety of CT for the prevention and management of CIPN. Method We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE. We included randomized trials with adults using CT for CIPN. Abstracts were screened, in¬clu¬sion criteria applied, data extracted, and risk of bias assessed. Evidence was determined by a pre-defined grading system. The grades indicated a high, moderate, or low net benefit, no demonstrated effect or suggested harm. Results Overall, 26 CT were identified. Depending on whether the CT was used for prevention or management and what kind of chemotherapeutic agent was applied, the picture was different: Glutathione and omega-3-fatty acids were categorized to grade B for the prevention of platinum-induced neuropathies, whereas for the prevention of taxane-induced neuropathies only omega-3-fatty acids were categorized to grade B and glutathione was suggested to potentially cause harm. Low-level laser therapy and neurofeedback were categorized to grade B for the management of both, platinum- and taxane-induced neuropathies. For details see Table 1 and 2. Conclusions Complementary therapies may be helpful when conventional treatment does not bring satisfactory relief or causes undesirable side effects in the prevention or management of CIPN. However, depending on the chemotherapeutic agent, CT could also cause harm.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.